CALGARY, Alberta--(BUSINESS WIRE)--March 23, 1999--SYNSORB Biotech Inc.
(''SYNSORB'') (TSE:SYB - news; NASDAQ:SYBB - news) today announced that effective
tomorrow before market opens, it has changed its Nasdaq ticker symbol to SYBB from
SYBBF.
''SYNSORB has always been and continues to be committed to accommodating our shareholders,'' said Dr. David Cox,
President and CEO of SYNSORB. ''This simplified ticker symbol further facilitates that goal.''
SYNSORB began trading on the Nasdaq National Market on February 25, 1998.
SYNSORB Biotech Inc. is dedicated to accelerated drug development from the acquisition of promising compounds emerging
from basic research through clinical development, and ultimately to providing channels to market for new discoveries.
Headquartered in Canada, SYNSORB currently has two products in late stage clinical trials, SYNSORB Pk® for the treatment
of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd® designed to treat recurrent
antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including potential
cancer treatments and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development
program.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other
factors not under the Company's control which may cause actual results, performance or achievements of the Company to be
materially different from the results, performance or expectations implied by these forward-looking statements. These factors
include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's
registration statement on Form 20 F filed with the Securities and Exchange Commission.
Contact:
SYNSORB Biotech Inc.
Mr. Doug Ball, 403/283-5900
403/283-5907 (FAX)
synsorb.com
or
The Equicom Group
Jason Hogan, 416/815-0700 ex 222
416/815-0080 (FAX)
United States: 800-385-5451
or
SYNSORB Biotech Inc.
Mr. Doug Froom, 403/283-5900
403/283-5907 (FAX)
|
